Page last updated: 2024-12-09

1-[(2-chlorophenyl)methyl]-3-methyl-N-(4-methyl-2-thiazolyl)-5-thieno[2,3-c]pyrazolecarboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're asking about a specific chemical compound: **1-[(2-chlorophenyl)methyl]-3-methyl-N-(4-methyl-2-thiazolyl)-5-thieno[2,3-c]pyrazolecarboxamide**.

Let's break down the name and potential importance:

**Chemical Structure:**

* **Thieno[2,3-c]pyrazole:** This is a fused ring system containing a thiophene (sulfur-containing) ring and a pyrazole ring.
* **Carboxamide:** This indicates a functional group (-CONH2) attached to the thieno[2,3-c]pyrazole system.
* **Substituents:**
* **1-[(2-chlorophenyl)methyl]:** A benzyl group (CH2-Ph) with a chlorine substituent at the ortho position of the phenyl ring attached at the 1-position of the pyrazole ring.
* **3-methyl:** A methyl group (CH3) at the 3-position of the pyrazole ring.
* **N-(4-methyl-2-thiazolyl):** A 4-methyl-2-thiazolyl group (CH3-thiazole) attached to the nitrogen atom of the carboxamide group.

**Importance in Research:**

The compound you described likely has potential pharmacological activity. Here's why:

* **Structural Features:** The presence of a thieno[2,3-c]pyrazole core, a carboxamide group, and various substituents suggests it could be a **scaffold for developing drugs** targeting specific biological targets.
* **Potential Targets:** The chemical structure resembles compounds that have shown activity against:
* **Cancer:** Thienopyrazoles have been investigated for their anticancer properties, particularly against leukemia and lung cancer.
* **Inflammatory Diseases:** The carboxamide group is often found in drugs that modulate inflammatory pathways.
* **Neurological Disorders:** Some thienopyrazoles exhibit activity in the central nervous system.
* **Infections:** Thiazoles are known for their antimicrobial and antifungal properties.

**Research Implications:**

* **Synthesis:** Chemists would need to synthesize this compound to study its properties.
* **Biological Assays:** Biological assays would be used to determine the compound's activity against different targets, such as cell lines or enzymes.
* **Pharmacokinetic Studies:** Research would investigate the compound's absorption, distribution, metabolism, and excretion in living organisms.
* **Safety and Toxicity Studies:** Extensive testing would be required to assess the compound's safety profile before it could be considered for clinical trials.

**Note:** Without further context, it's difficult to pinpoint the exact research importance of this specific compound. The chemical structure may be part of a larger library of compounds being screened, or it could be a lead compound with promising preliminary activity.

**To learn more about this compound, you'd need:**

* The research context in which it was discovered.
* The specific biological target it's intended to act on.
* The results of any studies that have been conducted on it.

Cross-References

ID SourceID
PubMed CID2082451
CHEMBL ID1465128
CHEBI ID104959

Synonyms (11)

Synonym
smr000256113
MLS000389839
CHEBI:104959
1-[(2-chlorophenyl)methyl]-3-methyl-n-(4-methyl-1,3-thiazol-2-yl)thieno[2,3-c]pyrazole-5-carboxamide
HMS2563B13
CHEMBL1465128
Z30818799
1-[(2-chlorophenyl)methyl]-3-methyl-n-(4-methyl-2-thiazolyl)-5-thieno[2,3-c]pyrazolecarboxamide
Q27182628
AKOS034143558
way-626365
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
thiophenesCompounds containing at least one thiophene ring.
aromatic amideAn amide in which the amide linkage is bonded directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency14.12540.003245.467312,589.2998AID2517
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
Chain A, CruzipainTrypanosoma cruziPotency25.11890.002014.677939.8107AID1476
LuciferasePhotinus pyralis (common eastern firefly)Potency10.69100.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency0.70790.01846.806014.1254AID624417
chaperonin-containing TCP-1 beta subunit homologHomo sapiens (human)Potency79.43283.981127.764939.8107AID504842
ATAD5 protein, partialHomo sapiens (human)Potency23.10930.004110.890331.5287AID504467
TDP1 proteinHomo sapiens (human)Potency18.47820.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency31.62280.180013.557439.8107AID1468
TSHR proteinHomo sapiens (human)Potency75.68630.338119.046637.9330AID602292
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
regulator of G-protein signaling 4Homo sapiens (human)Potency89.12510.531815.435837.6858AID504845
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency15.84890.001815.663839.8107AID894
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
huntingtin isoform 2Homo sapiens (human)Potency10.00000.000618.41981,122.0200AID1688
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency75.68630.425612.059128.1838AID504891
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency26.63210.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency19.70770.004611.374133.4983AID624296; AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency0.07080.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency31.62280.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency19.95260.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]